Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy

Summary

We plan to evaluate the efficacy and safety of proximal gastric vs. total gastric radical resection after SOX combined with anti-PD-1 neoadjuvant therapy in locally advanced upper gastric cancer

Conditions

• Locally Advanced Gastric Cancer

Interventions

PROCEDURE

Total radical gastrectomy

total radical gastrectomy : Dissection of lymph nodes No.1-7, 8a, 9, 11p, 11d, 12a are recommended. The tumor involved more than 3cm of esophagus and additional dissection No.19, 20, 110. Gastrointestinal reconstruction method: Roux⁃en⁃Y anastomosis is recommended

PROCEDURE

Proximal radical gastrectomy

Proximal radical gastrectomy : Dissection of lymph nodes No.1,2,3a,4sa,4sb,7,8a, 9, 11p, 11dare recommended. The tumor involved more than 3cm of esophagus and additional dissection No.19, 20, 110. Gastrointestinal reconstruction method: double channel anastomosis is recommended, and other anastomosis methods can be carried out according to the surgeon\'s habit.

Sponsors & Collaborators

• Fudan University

  collaborator OTHER

• Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

  collaborator OTHER

• Xiangya Hospital of Central South University

  collaborator OTHER

• Shandong First Medical University

  collaborator OTHER

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• The First Medical Center of Chinese PLA General Hospital

  collaborator OTHER

• Affiliated Hospital of Qinghai University

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Ruijin Hospital

  collaborator OTHER

• First Affiliated Hospital, Sun Yat-Sen University

  collaborator OTHER

• Southern Medical University, China

  collaborator OTHER

• Shanxi Bethune Hospital

  collaborator OTHER

• The First Affiliated Hospital of Zhengzhou University

  collaborator OTHER

• The Third Xiangya Hospital of Central South University

  collaborator OTHER

• Jingzhou Central Hospital

  collaborator OTHER

• Xiangyang Central Hospital

  collaborator OTHER

• Yichang Central People's Hospital

  collaborator OTHER

• The First Affiliated Hospital of University of South China

  collaborator OTHER

• Guangdong Provincial People's Hospital

  collaborator OTHER

• People's Hospital of Macheng City

  collaborator UNKNOWN

• Southwest Hospital, China

  collaborator OTHER

• Liaoning Cancer Hospital & Institute

  collaborator OTHER

• RenJi Hospital

  collaborator OTHER

• Changhai Hospital

  collaborator OTHER

• The First Affilated Hospital of the Medical College, Shihezi University

  collaborator OTHER

• First Affiliated Hospital Xi'an Jiaotong University

  collaborator OTHER

• First Affiliated Hospital of Xinjiang Medical University

  collaborator OTHER

• Sixth Affiliated Hospital, Sun Yat-sen University

  collaborator OTHER

• First Hospital of China Medical University

  collaborator OTHER

• Shanghai East Hospital

  collaborator OTHER

• General Hospital of Ningxia Medical University

  collaborator OTHER

• Shanghai Changzheng Hospital

  collaborator OTHER

• Guihua Wang

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-03-01

Primary Completion

2026-12-30

Completion

2028-12-30

Countries

• China

Study Locations